Life Expectancy of People with HIV on Antiretroviral Therapy in Spain
Inmaculada Jarrín(Instituto de Salud Carlos III), Julia del Amo(Government of Spain), Antonio Rivero(University of Southern California), Javier Martínez‐Sanz(Instituto de Salud Carlos III), José Ramón Blanco, Marta Rava(Instituto de Salud Carlos III), María Lagarde(Instituto de Salud Carlos III), Jorge del Romero Raposo(Centro Nacional de Epidemiología), David Dalmau(University Hospital Mútua de Terrassa), Gemma Navarro(Corporació Sanitària Parc Taulí), Javier Gómez Castellá(Ministry of Health), Jorge del Romero Guerrero(Hospital Clínico San Carlos), Ana Koerting(Government of Spain)
Cited by 6
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198